Trump Administration to Examine Ibogaine Research for PTSD Funding
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy PBM?
Source: stocktwits
- Government Focus on Ibogaine: The Trump administration plans to closely examine ibogaine's safety and effectiveness, maintaining its Schedule I classification, which indicates a cautious approach to its potential medical applications.
- Research Funding Opening: President Trump is expected to sign an executive order aimed at unlocking federal funding for research into ibogaine's effectiveness for PTSD and traumatic brain injuries, particularly among veterans, signaling a significant policy shift.
- Stock Price Surge: Following the news, shares of Psyence Biomedical (PBM) surged over 141% on Thursday, potentially marking its best trading session, reflecting strong market confidence in the company's natural-derived therapies.
- Market Sentiment Extremely Bullish: On Stocktwits, retail sentiment around PBM stock remained in the 'extremely bullish' territory with message volume spiking, despite the stock having fallen approximately 95% over the past year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PBM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PBM
About PBM
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Administration to Examine Ibogaine Research for PTSD Funding
- Government Focus on Ibogaine: The Trump administration plans to closely examine ibogaine's safety and effectiveness, maintaining its Schedule I classification, which indicates a cautious approach to its potential medical applications.
- Research Funding Opening: President Trump is expected to sign an executive order aimed at unlocking federal funding for research into ibogaine's effectiveness for PTSD and traumatic brain injuries, particularly among veterans, signaling a significant policy shift.
- Stock Price Surge: Following the news, shares of Psyence Biomedical (PBM) surged over 141% on Thursday, potentially marking its best trading session, reflecting strong market confidence in the company's natural-derived therapies.
- Market Sentiment Extremely Bullish: On Stocktwits, retail sentiment around PBM stock remained in the 'extremely bullish' territory with message volume spiking, despite the stock having fallen approximately 95% over the past year.
See More
Psyence BioMed Expands Clinical Network to Five Sites in Australia
- Clinical Network Expansion: Psyence BioMed expands its clinical sites in Australia from three to five, adding Ramsay Health Care and NeuroCentrix, which enhances collaboration with experienced hospital and research partners, thereby improving the execution capability and data generation potential of its clinical programs.
- Trial Progress: The ongoing Phase IIb clinical trial evaluates natural psilocybin for treating Adjustment Disorder in cancer patients, with the addition of new sites expected to accelerate patient recruitment and enrollment, further advancing the multi-site trial.
- Drug Supply Assurance: Psyence BioMed supplies GMP-compliant psilocybin product NPX-5, ensuring drug availability for the clinical trial, supporting ongoing patient dosing, and enhancing operational efficiency and geographic reach.
- Strategic Partnerships: CEO Jody Aufrichtig stated that the addition of high-quality clinical partners will strengthen the company's execution capabilities, accelerate enrollment processes, and provide crucial support for generating clinical data, ensuring the company's continued growth in the mental health sector.
See More
Psyence BioMed Successfully Exports GMP-Compliant Psychedelic Product
- Export Achievement: Psyence BioMed successfully exported GMP-compliant psychedelic product NPX-5 (1mg and 5mg capsules) to Australia, marking a significant milestone in the establishment of a global supply chain and reinforcing its leadership in nature-derived psychedelics.
- Clinical Trial Advancement: The exported NPX-5 will be utilized in an ongoing Phase IIb clinical trial in Australia involving 87 cancer patients, aimed at evaluating the efficacy of natural psilocybin for Adjustment Disorder, showcasing the company's innovative capabilities and market potential in mental health.
- Manufacturing and Compliance Edge: PsyLabs' GMP-compliant production facility ensures high-quality and compliant products, with the successful export validating its operational readiness and laying the groundwork for future international market expansion, enhancing the company's competitiveness in the psychedelic sector.
- Strategic Integration and Investment: The close collaboration between Psyence BioMed and PsyLabs reflects its vertical integration strategy in the psychedelic space, with ongoing technological investments and compliant operations expected to drive sustainable growth in the global market.
See More
Vanda Pharmaceuticals Shares Surge 33% in Pre-Market Trading
- Significant Price Surge: Vanda Pharmaceuticals' shares jumped 33% in pre-market trading to $7.65, indicating strong market confidence in its future performance, which may attract more investor interest.
- Positive Market Reaction: This price surge reflects optimistic expectations from investors regarding Vanda's potential growth opportunities, potentially facilitating further development in the biopharmaceutical sector.
- Increased Trading Activity: With the notable price increase, Vanda's trading volume is likely to rise, providing the company with enhanced liquidity to support its R&D and market expansion plans.
- Improved Investor Sentiment: The rise in Vanda's stock price may enhance overall investor sentiment, particularly in the biopharmaceutical industry, further boosting the performance of related stocks.
See More
Psyence BioMed Exercises Put Option to Invest in PsyLabs
- Equity Investment Agreement: Psyence BioMed will make an equity investment in PsyLabs under a previously disclosed put option agreement, which is expected to enhance strategic alignment between the two companies and support Psyence BioMed's long-term supply strategy.
- Transaction Details: The deal involves Psyence BioMed acquiring 2,900 shares of PsyLabs for a subscription amount of $5 million, reflecting a fair market valuation of $1,724 per share, while PsyLabs will receive 1,146,159 PBM shares calculated at a 30-day VWAP of $4.36 per share.
- Shareholder Structure Change: Following the transaction, PsyLabs will own approximately 49.98% of Psyence BioMed's shares, which could significantly influence governance and control dynamics, increasing its impact on shareholder decisions.
- Strategic Implications: This investment reflects the ongoing evolution of the strategic relationship between the parties and underscores Psyence BioMed's commitment to securing high-quality pharmaceutical manufacturing capabilities to support its clinical and commercialization programs.
See More
Psyence BioMed Announces Shareholder Meeting Voting Results
- Voting Results: Psyence BioMed held its Annual Meeting on February 12, 2026, where all proposals, including director elections and auditor appointments, were approved, indicating strong shareholder support for corporate governance.
- Auditor Appointment: Shareholders approved MNP LLP as the company's auditors for the upcoming year and authorized the Board to determine the auditors' remuneration, ensuring financial transparency and compliance.
- Share Consolidation Authorization: A special resolution was passed allowing the Board to implement share consolidations of up to 250:1, which could impact the company's capital structure and enhance per-share value.
- Future Disclosure Commitment: The company committed to providing further details regarding the share consolidation, including the final ratio and effective date, ensuring shareholders are informed about significant decisions.
See More
Trump Administration to Examine Ibogaine Research for PTSD Funding
- Government Focus on Ibogaine: The Trump administration plans to closely examine ibogaine's safety and effectiveness, maintaining its Schedule I classification, which indicates a cautious approach to its potential medical applications.
- Research Funding Opening: President Trump is expected to sign an executive order aimed at unlocking federal funding for research into ibogaine's effectiveness for PTSD and traumatic brain injuries, particularly among veterans, signaling a significant policy shift.
- Stock Price Surge: Following the news, shares of Psyence Biomedical (PBM) surged over 141% on Thursday, potentially marking its best trading session, reflecting strong market confidence in the company's natural-derived therapies.
- Market Sentiment Extremely Bullish: On Stocktwits, retail sentiment around PBM stock remained in the 'extremely bullish' territory with message volume spiking, despite the stock having fallen approximately 95% over the past year.
See More
Psyence BioMed Expands Clinical Network to Five Sites in Australia
- Clinical Network Expansion: Psyence BioMed expands its clinical sites in Australia from three to five, adding Ramsay Health Care and NeuroCentrix, which enhances collaboration with experienced hospital and research partners, thereby improving the execution capability and data generation potential of its clinical programs.
- Trial Progress: The ongoing Phase IIb clinical trial evaluates natural psilocybin for treating Adjustment Disorder in cancer patients, with the addition of new sites expected to accelerate patient recruitment and enrollment, further advancing the multi-site trial.
- Drug Supply Assurance: Psyence BioMed supplies GMP-compliant psilocybin product NPX-5, ensuring drug availability for the clinical trial, supporting ongoing patient dosing, and enhancing operational efficiency and geographic reach.
- Strategic Partnerships: CEO Jody Aufrichtig stated that the addition of high-quality clinical partners will strengthen the company's execution capabilities, accelerate enrollment processes, and provide crucial support for generating clinical data, ensuring the company's continued growth in the mental health sector.
See More
Psyence BioMed Successfully Exports GMP-Compliant Psychedelic Product
- Export Achievement: Psyence BioMed successfully exported GMP-compliant psychedelic product NPX-5 (1mg and 5mg capsules) to Australia, marking a significant milestone in the establishment of a global supply chain and reinforcing its leadership in nature-derived psychedelics.
- Clinical Trial Advancement: The exported NPX-5 will be utilized in an ongoing Phase IIb clinical trial in Australia involving 87 cancer patients, aimed at evaluating the efficacy of natural psilocybin for Adjustment Disorder, showcasing the company's innovative capabilities and market potential in mental health.
- Manufacturing and Compliance Edge: PsyLabs' GMP-compliant production facility ensures high-quality and compliant products, with the successful export validating its operational readiness and laying the groundwork for future international market expansion, enhancing the company's competitiveness in the psychedelic sector.
- Strategic Integration and Investment: The close collaboration between Psyence BioMed and PsyLabs reflects its vertical integration strategy in the psychedelic space, with ongoing technological investments and compliant operations expected to drive sustainable growth in the global market.
See More
Vanda Pharmaceuticals Shares Surge 33% in Pre-Market Trading
- Significant Price Surge: Vanda Pharmaceuticals' shares jumped 33% in pre-market trading to $7.65, indicating strong market confidence in its future performance, which may attract more investor interest.
- Positive Market Reaction: This price surge reflects optimistic expectations from investors regarding Vanda's potential growth opportunities, potentially facilitating further development in the biopharmaceutical sector.
- Increased Trading Activity: With the notable price increase, Vanda's trading volume is likely to rise, providing the company with enhanced liquidity to support its R&D and market expansion plans.
- Improved Investor Sentiment: The rise in Vanda's stock price may enhance overall investor sentiment, particularly in the biopharmaceutical industry, further boosting the performance of related stocks.
See More
Psyence BioMed Exercises Put Option to Invest in PsyLabs
- Equity Investment Agreement: Psyence BioMed will make an equity investment in PsyLabs under a previously disclosed put option agreement, which is expected to enhance strategic alignment between the two companies and support Psyence BioMed's long-term supply strategy.
- Transaction Details: The deal involves Psyence BioMed acquiring 2,900 shares of PsyLabs for a subscription amount of $5 million, reflecting a fair market valuation of $1,724 per share, while PsyLabs will receive 1,146,159 PBM shares calculated at a 30-day VWAP of $4.36 per share.
- Shareholder Structure Change: Following the transaction, PsyLabs will own approximately 49.98% of Psyence BioMed's shares, which could significantly influence governance and control dynamics, increasing its impact on shareholder decisions.
- Strategic Implications: This investment reflects the ongoing evolution of the strategic relationship between the parties and underscores Psyence BioMed's commitment to securing high-quality pharmaceutical manufacturing capabilities to support its clinical and commercialization programs.
See More
Psyence BioMed Announces Shareholder Meeting Voting Results
- Voting Results: Psyence BioMed held its Annual Meeting on February 12, 2026, where all proposals, including director elections and auditor appointments, were approved, indicating strong shareholder support for corporate governance.
- Auditor Appointment: Shareholders approved MNP LLP as the company's auditors for the upcoming year and authorized the Board to determine the auditors' remuneration, ensuring financial transparency and compliance.
- Share Consolidation Authorization: A special resolution was passed allowing the Board to implement share consolidations of up to 250:1, which could impact the company's capital structure and enhance per-share value.
- Future Disclosure Commitment: The company committed to providing further details regarding the share consolidation, including the final ratio and effective date, ensuring shareholders are informed about significant decisions.
See More
